- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03855514
Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers (DFUs)
A Prospective, Multicenter, Randomized, Controlled Clinical Study Of NuShield® and Standard of Care (SOC) Compared to SOC Alone For The Management Of Diabetic Foot Ulcers
Study Overview
Detailed Description
Two hundred (200) subjects with a chronic DFU ranging in size from 0.5cm2 and 25 cm2 will be randomized 1:1 to either NuShield® and SOC or SOC alone following the 14 day screening period. Following screening and randomization, subjects shall be seen weekly for up to 24 weeks. For subjects that heal prior to week 24, a healing confirmation visit shall occur two weeks later to confirm maintenance of complete wound closure.
Subjects that are randomized into the SOC group whose DFU has not healed by week 12 may be crossed over to receive NuShield® and followed for an additional 12-14 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Galen Hale
- Phone Number: (205) 541-9682
- Email: GHale@organo.com
Study Contact Backup
- Name: Andrea Black
- Phone Number: (781) 830-2364
- Email: ABlack@organo.com
Study Locations
-
-
California
-
Carlsbad, California, United States, 92002
- Recruiting
- ILD Research Center
-
Contact:
- Eric Martinez
- Email: eric@ildresearch.com
-
Principal Investigator:
- Dean Vayser, DPM
-
Fresno, California, United States, 94063
- Recruiting
- Limb Preservation Platform
-
Contact:
- Destiny Blackstone
- Email: destiny@lppresearch.com
-
Los Angeles, California, United States, 91208
- Recruiting
- University of Southern California
-
Contact:
- Karen DHuyvetter
- Email: Karen.DHuyvetter@med.usc.edu
-
Principal Investigator:
- David Armstrong
-
Redwood City, California, United States, 94063
- Recruiting
- Stanford University
-
Contact:
- Shannon Meyer
- Email: smeyer27@stanford.edu
-
Principal Investigator:
- Geoffrey Gurtner
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06606
- Recruiting
- Family Foot & Ankle Specialists
-
Contact:
- Catherine Porter
- Email: familypodiatryct@gmail.com
-
Principal Investigator:
- Daniel Davis
-
-
Florida
-
Miami, Florida, United States, 33143
- Recruiting
- Doctors Research Network
-
Principal Investigator:
- Jason Hanft
-
Contact:
- Nara Neiva
- Email: nneiva@miamifoot.com
-
-
Georgia
-
Roswell, Georgia, United States, 30076
- Recruiting
- Extremity Healthcare
-
Contact:
- Amelia Sobhani
- Email: asobhani@vpcenters.com
-
Principal Investigator:
- Ira Kraus
-
-
New York
-
New York, New York, United States, 11501
- Recruiting
- NYU Winthrop Hospital
-
Contact:
- Helen Yiu
- Email: helen.yiu@nyulangone.org
-
Principal Investigator:
- Scott Gorenstein
-
-
Texas
-
McAllen, Texas, United States, 78501
- Recruiting
- Futuro Clinical Trials
-
Contact:
- Chrissy Rodriguez
- Email: chrissycffc@gmail.com
-
Principal Investigator:
- Joseph Caporusso
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years old and maximum of 85 years old.
- Subjects with a diabetic foot ulcer that is either superficial, e.g. not involving tendon, capsule, or bone; or wounds that penetrate into tendon, capsule, bone and/or joint.
- Subjects, with the presence of Diabetes, must have a Glycosylated hemoglobin (HbA1c) ≤ 12% within 4 weeks prior to randomization
- Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to the initial screening visit with no upper limit in duration of non-healing.
- Subject has adequate circulation to the foot as documented by either: Skin perfusion pressure (SPP) measurement of ≥ 45 mmHg, Toe-brachial index (TBI) ≥ 0.6/ Toe pressure greater than 40, Ankle-brachial index (ABI) between 0.60 and ≤ 1.3
- Index ulcer is a minimum of 0.5 cm2 and a maximum of 25cm2 at randomization, prior to first study treatment.
- The index ulcer has been offloaded for 14 days prior to randomization.
- Index ulcer has not reduced in area > 20% from Day -14 to Day 0, prior to randomization.
- Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
- Subject, or their Legally Authorized Representative (LAR), has read, understood, and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.
Exclusion Criteria:
- Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.
- Treatment with HBO wound dressings that include growth factors, bioengineered tissues, or skin substitutes within 30 days of randomization.
- History of bone cancer or metastatic disease of the affected limb or chemotherapy within the 12 months prior to randomization.
- Subjects with a history of more than two weeks treatment with immunosuppressants (including prednisone 10 mg daily or an equivalent does of other oral steroids cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
- Subject is on any investigational drug(s) or therapeutic device(s) within 30 days preceding the first Screening Visit.
- History of radiation at the ulcer site.
- Index ulcer has been previously treated or will need to be treated with any prohibited therapies within 30 days prior to randomization.
- Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
- Active infection at the index ulcer at the time of Randomization.
- Acute osteomyelitis or bone infection of the affected foot, where subject has received less than 4 weeks of systemic antibiotics at the time of Screening and less than 6 weeks prior to Randomization (systemic antibiotic regimen must be completed at the time of Randomization).
- Subject's with suspected infection who have received less than 2 weeks of systemic antibiotics, or have not had surgical resection of clinically diagnosed osteomyelitis
- Subjects with suspected osteomyelitis who have not had an X-ray, CT scan or MRI within 14 days prior to Randomization.
- Subject is unwilling or unable to comply with the study requirement for offloading the index wound
- Subject is pregnant or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: NuShield
NuShield® is a sterile, dehydrated placental allograft
|
NuShield® is a dehydrated placental allograft.
|
No Intervention: Standard of Care
Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of time that a wound achieves complete wound closure (CWC)
Time Frame: 12 weeks
|
Duration (number of days) to achieve CWC from baseline to week 12 assessed between both groups
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Greater than 40% wound closure at week 4 from baseline
Time Frame: 4 weeks
|
Proportion of subjects achieving ≥ 40% wound closure at Week 4 from baseline
|
4 weeks
|
Change in wound area
Time Frame: 12 weeks
|
Mean percent change from baseline in wound area at Week 12
|
12 weeks
|
Incidence of prescribed pain and/or neuropathic medications
Time Frame: 12 weeks
|
Cumulative amount of pain and neuropathic medications taken between baseline and Week 12 assessed between both groups.
|
12 weeks
|
Reduction in subject reported pain at week 12 from baseline assessed between both groups via the Numeric Pain Rating Scale (NPRS)
Time Frame: 12 weeks
|
Mean percent change at week 12 in subject reported pain, assessed via the NPRS pain scale where 0 = no pain and 10 = worst pain imaginable, on a scale of 0 to 10.
|
12 weeks
|
Utilization of healthcare resources assessment
Time Frame: 12 weeks
|
Utilization of healthcare resources through Week 12
|
12 weeks
|
Improvement in subject reported quality of life at week 12 from baseline assessed via the Wound-QoL (Questionnaire on quality of life with chronic wounds).
Time Frame: 12 weeks
|
Mean percent change at week 12 from baseline in subject reported quality of life scores between both groups.
The 17 item Wound-QoL tool measures the disease-specific, health-related quality of life of patients with chronic wounds.
A global score is computed by averaging all 17 items where subjects answer each question on a scale of 0 to 4, where 0=not at all and 4=very much.
|
12 weeks
|
Time to complete wound closure (CWC) by or on 24 weeks
Time Frame: 24 weeks
|
Length of time wounds achieve CWC at week 24 from baseline
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Christine McLennan, Organogenesis Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-DFU-005-NUS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on NuShield
-
NuTech Medical, IncOrganogenesisUnknown
-
NuTech Medical, IncOrganogenesisCompletedFoot Ulcer, DiabeticUnited States